Literature DB >> 1733504

Inhibition of experimental autoimmune uveitis by retinal photoreceptor antigens coupled to spleen cells.

H S Dua1, D S Gregerson, L A Donoso.   

Abstract

Experimental autoimmune uveitis (EAU) and experimental autoimmune pinealitis (EAP) are CD4+ T cell-mediated inflammatory diseases of the uveal tract and retina of the eye and of the pineal gland. EAU and EAP can be induced by several retinal autoantigens including S-antigen (S-Ag) and interphotoreceptor retinoid binding protein (IRBP). In this study we investigated the effect of intravenous administration of S-Ag and IRBP coupled to syngeneic spleen cells on the development of EAU and EAP. Injection of S-Ag or IRBP coupled to spleen cells 5 days prior to immunization with native S-Ag or IRBP, respectively, was effective in preventing the induction of EAU and EAP in LEW rats. Conversely, LEW rats receiving S-Ag-coupled spleen cells and challenged with IRBP or LEW rats receiving IRBP-coupled spleen cells and challenged with S-Ag developed a severe EAU within 10 days to 2 weeks following immunization, as did all control animals receiving sham-coupled spleen cells and challenged with the two retinal antigens. The results show that the administration of retinal autoantigens coupled to spleen cells effectively protects against the development of EAU when animals are subsequently challenged with the tolerizing antigen but not when challenged with another unrelated pathogenic retinal autoantigen.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1733504     DOI: 10.1016/0008-8749(92)90072-w

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  10 in total

Review 1.  Advancing islet transplantation: from engraftment to the immune response.

Authors:  R F Gibly; J G Graham; X Luo; W L Lowe; B J Hering; L D Shea
Journal:  Diabetologia       Date:  2011-08-10       Impact factor: 10.122

Review 2.  Molecular mechanisms of T-cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy.

Authors:  Joseph R Podojil; Stephen D Miller
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

3.  Induction of tolerance by T-cell vaccination is possible beyond the area of autoimmunity: down-regulation of immunity directed to foreign protein antigens.

Authors:  M J Jacobs; A E van den Hoek; L B van de Putte; W B van den Berg
Journal:  Immunology       Date:  1993-12       Impact factor: 7.397

4.  Nasal administration of retinal antigens suppresses the inflammatory response in experimental allergic uveoretinitis. A preliminary report of intranasal induction of tolerance with retinal antigens.

Authors:  A D Dick; Y F Cheng; A McKinnon; J Liversidge; J V Forrester
Journal:  Br J Ophthalmol       Date:  1993-03       Impact factor: 4.638

Review 5.  Overcoming challenges in treating autoimmuntity: Development of tolerogenic immune-modifying nanoparticles.

Authors:  Ryan M Pearson; Joseph R Podojil; Lonnie D Shea; Nicholas J C King; Stephen D Miller; Daniel R Getts
Journal:  Nanomedicine       Date:  2018-10-21       Impact factor: 5.307

6.  Spontaneous development of a pancreatic exocrine disease in CD28-deficient NOD mice.

Authors:  Craig Meagher; Qizhi Tang; Brian T Fife; Helene Bour-Jordan; Jenny Wu; Cecile Pardoux; Mingying Bi; Kristin Melli; Jeffrey A Bluestone
Journal:  J Immunol       Date:  2008-06-15       Impact factor: 5.422

Review 7.  Prospects for antigen-specific tolerance based therapies for the treatment of multiple sclerosis.

Authors:  Danielle M Turley; Stephen D Miller
Journal:  Results Probl Cell Differ       Date:  2010

8.  Intranasal administration of retinal antigens suppresses retinal antigen-induced experimental autoimmune uveoretinitis.

Authors:  A D Dick; Y F Cheng; J Liversidge; J V Forrester
Journal:  Immunology       Date:  1994-08       Impact factor: 7.397

Review 9.  Therapeutic blockade of T-cell antigen receptor signal transduction and costimulation in autoimmune disease.

Authors:  Joseph R Podojil; Danielle M Turley; Stephen D Miller
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

Review 10.  Emerging Therapeutics for Immune Tolerance: Tolerogenic Vaccines, T cell Therapy, and IL-2 Therapy.

Authors:  Cody D Moorman; Sue J Sohn; Hyewon Phee
Journal:  Front Immunol       Date:  2021-03-29       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.